{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T12:50:55Z","timestamp":1770814255725,"version":"3.50.1"},"reference-count":64,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T00:00:00Z","timestamp":1768435200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T00:00:00Z","timestamp":1770681600000},"content-version":"vor","delay-in-days":26,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Gastroenterol"],"DOI":"10.1186\/s12876-026-04610-1","type":"journal-article","created":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T07:05:57Z","timestamp":1768460757000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Tofogliflozin attenuates liver steatosis and fibrosis in non-diabetic non-alcoholic steatohepatitis mice"],"prefix":"10.1186","volume":"26","author":[{"given":"Yoshinori","family":"Ozono","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Kawakami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Hatada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naomi","family":"Uchiyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Souichiro","family":"Ogawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keisuke","family":"Uchida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hotaka","family":"Tamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuri","family":"Komaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenichi","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hisayoshi","family":"Iwakiri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoru","family":"Hasuike","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenji","family":"Nagata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,15]]},"reference":[{"key":"4610_CR1","doi-asserted-by":"publisher","first-page":"103043","DOI":"10.1016\/j.arcmed.2024.103043","volume":"55","author":"E Amini-Salehi","year":"2024","unstructured":"Amini-Salehi E, Letafatkar N, Norouzi N, et al. Global prevalence of nonalcoholic fatty liver disease: an updated review meta-analysis comprising a population of 78 million from 38 countries. Arch Med Res. 2024;55:103043. https:\/\/doi.org\/10.1016\/j.arcmed.2024.103043.","journal-title":"Arch Med Res"},{"key":"4610_CR2","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1002\/hep.27368","volume":"61","author":"M Ekstedt","year":"2015","unstructured":"Ekstedt M, Hagstr\u00f6m H, Nasr P, et al. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. Hepatology. 2015;61:1547\u201354. https:\/\/doi.org\/10.1002\/hep.27368.","journal-title":"Hepatology"},{"key":"4610_CR3","doi-asserted-by":"publisher","first-page":"615978","DOI":"10.3389\/fmed.2021.615978","volume":"8","author":"LJM Heyens","year":"2021","unstructured":"Heyens LJM, Busschots D, Koek GH, et al. Liver fibrosis in non-alcoholic fatty liver disease: from liver biopsy to non-invasive biomarkers in diagnosis and treatment. Front Med (Lausanne). 2021;8:615978. https:\/\/doi.org\/10.3389\/fmed.2021.615978.","journal-title":"Front Med (Lausanne)"},{"key":"4610_CR4","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1053\/j.gastro.2015.04.043","volume":"149","author":"P Angulo","year":"2015","unstructured":"Angulo P, Kleiner DE, Dam-Larsen S, et al. Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology. 2015;149:389\u201397. https:\/\/doi.org\/10.1053\/j.gastro.2015.04.043.","journal-title":"Gastroenterology"},{"key":"4610_CR5","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1056\/NEJMoa2029349","volume":"385","author":"AJ Sanyal","year":"2021","unstructured":"Sanyal AJ, Van Natta ML, Clark J, et al. Prospective study of outcomes in adults with nonalcoholic fatty liver disease. N Engl J Med. 2021;385:1559\u201369. https:\/\/doi.org\/10.1056\/NEJMoa2029349.","journal-title":"N Engl J Med"},{"key":"4610_CR6","doi-asserted-by":"publisher","first-page":"222","DOI":"10.14218\/JCTH.2020.00026","volume":"8","author":"Y Chang","year":"2020","unstructured":"Chang Y, Li H. Hepatic antifibrotic pharmacotherapy: are we approaching success? J Clin Transl Hepatol. 2020;8:222\u20139. https:\/\/doi.org\/10.14218\/JCTH.2020.00026.","journal-title":"J Clin Transl Hepatol"},{"key":"4610_CR7","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1053\/j.gastro.2023.04.025","volume":"165","author":"DQ Huang","year":"2023","unstructured":"Huang DQ, Wilson LA, Behling C, et al. Fibrosis progression rate in biopsy-proven nonalcoholic fatty liver disease among people with diabetes versus people without diabetes: a multicenter study. Gastroenterology. 2023;165:463\u201372. https:\/\/doi.org\/10.1053\/j.gastro.2023.04.025.","journal-title":"Gastroenterology"},{"key":"4610_CR8","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1002\/hep.31806","volume":"74","author":"AS Alexopoulos","year":"2021","unstructured":"Alexopoulos AS, Crowley MJ, Wang Y, et al. Glycemic control predicts severity of hepatocyte ballooning and hepatic fibrosis in nonalcoholic fatty liver disease. Hepatology. 2021;74:1220\u201333. https:\/\/doi.org\/10.1002\/hep.31806.","journal-title":"Hepatology"},{"key":"4610_CR9","doi-asserted-by":"publisher","first-page":"565","DOI":"10.3350\/cmh.2022.0096","volume":"28","author":"CH Ng","year":"2022","unstructured":"Ng CH, Chan KE, Chin YH, et al. The effect of diabetes and prediabetes on the prevalence, complications and mortality in nonalcoholic fatty liver disease. Clin Mol Hepatol. 2022;28:565\u201374. https:\/\/doi.org\/10.3350\/cmh.2022.0096.","journal-title":"Clin Mol Hepatol"},{"key":"4610_CR10","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1002\/hep.28431","volume":"64","author":"ZM Younossi","year":"2016","unstructured":"Younossi ZM, Koenig AB, Abdelatif D, et al. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64:73\u201384. https:\/\/doi.org\/10.1002\/hep.28431.","journal-title":"Hepatology"},{"key":"4610_CR11","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1007\/s00535-013-0911-1","volume":"49","author":"T Nakahara","year":"2014","unstructured":"Nakahara T, Hyogo H, Yoneda M, et al. Type 2 diabetes mellitus is associated with the fibrosis severity in patients with nonalcoholic fatty liver disease in a large retrospective cohort of Japanese patients. J Gastroenterol. 2014;49:1477\u201384. https:\/\/doi.org\/10.1007\/s00535-013-0911-1.","journal-title":"J Gastroenterol"},{"key":"4610_CR12","doi-asserted-by":"publisher","unstructured":"Golabi P, Paik JM, Kumar A et al Nonalcoholic fatty liver disease (NAFLD) and associated mortality in individuals with type 2 diabetes, pre-diabetes, metabolically unhealthy, and metabolically healthy individuals in the united States. Metabolism. 2023;146155642. https:\/\/doi.org\/10.1016\/j.metabol.2023.155642.","DOI":"10.1016\/j.metabol.2023.155642"},{"key":"4610_CR13","doi-asserted-by":"publisher","first-page":"3263","DOI":"10.1016\/j.bmc.2012.03.051","volume":"20","author":"M Imamura","year":"2012","unstructured":"Imamura M, Nakanishi K, Suzuki T, et al. Discovery of Ipragliflozin (ASP1941): a novel C-glucoside with benzothiophene structure as a potent and selective sodium glucose co-transporter 2 (SGLT-2) inhibitor for the treatment of type 2 diabetes mellitus. Bioorg Med Chem. 2012;20:3263\u201379. https:\/\/doi.org\/10.1016\/j.bmc.2012.03.051.","journal-title":"Bioorg Med Chem"},{"key":"4610_CR14","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1007\/s00210-011-0713-z","volume":"385","author":"A Tahara","year":"2012","unstructured":"Tahara A, Kurosaki E, Yokono M, et al. Pharmacological profile of Ipragliflozin (ASP1941), a novel selective SGLT-2 inhibitor, in vitro and in vivo. Naunyn Schmiedebergs Arch Pharmacol. 2012;385:423\u201336. https:\/\/doi.org\/10.1007\/s00210-011-0713-z.","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"4610_CR15","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1111\/jdi.12980","volume":"10","author":"M Inoue","year":"2019","unstructured":"Inoue M, Hayashi A, Taguchi T, et al. Effects of Canagliflozin on body composition and hepatic fat content in type 2 diabetes patients with non-alcoholic fatty liver disease. J Diabetes Investig. 2019;10:1004\u201311. https:\/\/doi.org\/10.1111\/jdi.12980.","journal-title":"J Diabetes Investig"},{"key":"4610_CR16","doi-asserted-by":"publisher","first-page":"3391","DOI":"10.2169\/internalmedicine.7134-21","volume":"60","author":"N Nishimiya","year":"2021","unstructured":"Nishimiya N, Tajima K, Imajo K, et al. Effects of Canagliflozin on hepatic steatosis, visceral fat and skeletal muscle among patients with type 2 diabetes and non-alcoholic fatty liver disease. Intern Med. 2021;60:3391\u201399. https:\/\/doi.org\/10.2169\/internalmedicine.7134-21.","journal-title":"Intern Med"},{"key":"4610_CR17","doi-asserted-by":"publisher","unstructured":"Seko Y, Nishikawa T, Umemura A et al Efficacy and safety of Canagliflozin in type 2 diabetes mellitus patients with biopsy-proven nonalcoholic steatohepatitis classified as stage 1\u20133 fibrosis. Diabetes Metab Syndr Obes. 2018;11835\u201343. https:\/\/doi.org\/10.2147\/DMSO.S184767.","DOI":"10.2147\/DMSO.S184767"},{"key":"4610_CR18","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1111\/dom.13520","volume":"21","author":"M Shimizu","year":"2019","unstructured":"Shimizu M, Suzuki K, Kato K, et al. Evaluation of the effects of dapagliflozin, a sodium-glucose co-transporter-2 inhibitor, on hepatic steatosis and fibrosis using transient elastography in patients with type 2 diabetes and non-alcoholic fatty liver disease. Diabetes Obes Metab. 2019;21:285\u201392. https:\/\/doi.org\/10.1111\/dom.13520.","journal-title":"Diabetes Obes Metab"},{"key":"4610_CR19","doi-asserted-by":"publisher","first-page":"1923","DOI":"10.1007\/s00125-018-4675-2","volume":"61","author":"JW Eriksson","year":"2018","unstructured":"Eriksson JW, Lundkvist P, Jansson PA, et al. Effects of Dapagliflozin and n-3 carboxylic acids on non-alcoholic fatty liver disease in people with type 2 diabetes: a double-blind randomised placebo-controlled study. Diabetologia. 2018;61:1923\u201334. https:\/\/doi.org\/10.1007\/s00125-018-4675-2.","journal-title":"Diabetologia"},{"key":"4610_CR20","doi-asserted-by":"publisher","first-page":"2952","DOI":"10.1111\/jgh.15580","volume":"36","author":"S Phrueksotsai","year":"2021","unstructured":"Phrueksotsai S, Pinyopornpanish K, Euathrongchit J, et al. The effects of Dapagliflozin on hepatic and visceral fat in type 2 diabetes patients with non-alcoholic fatty liver disease. J Gastroenterol Hepatol. 2021;36:2952\u20139. https:\/\/doi.org\/10.1111\/jgh.15580.","journal-title":"J Gastroenterol Hepatol"},{"key":"4610_CR21","doi-asserted-by":"publisher","first-page":"173","DOI":"10.3164\/jcbn.20-129","volume":"68","author":"H Tobita","year":"2021","unstructured":"Tobita H, Yazaki T, Kataoka M, et al. Comparison of Dapagliflozin and teneligliptin in nonalcoholic fatty liver disease patients without type 2 diabetes mellitus: a prospective randomized study. J Clin Biochem Nutr. 2021;68:173\u201380. https:\/\/doi.org\/10.3164\/jcbn.20-129.","journal-title":"J Clin Biochem Nutr"},{"key":"4610_CR22","doi-asserted-by":"publisher","first-page":"4697","DOI":"10.1007\/s12325-020-01498-5","volume":"37","author":"H Taheri","year":"2020","unstructured":"Taheri H, Malek M, Ismail-Beigi F, et al. Effect of empagliflozin on liver steatosis and fibrosis in patients with non-alcoholic fatty liver disease without diabetes: a randomized, double-blind, placebo-controlled trial. Adv Ther. 2020;37:4697\u2013708. https:\/\/doi.org\/10.1007\/s12325-020-01498-5.","journal-title":"Adv Ther"},{"key":"4610_CR23","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1007\/s13300-021-01011-3","volume":"12","author":"H Chehrehgosha","year":"2021","unstructured":"Chehrehgosha H, Sohrabi MR, Ismail-Beigi F, et al. Empagliflozin improves liver steatosis and fibrosis in patients with non-alcoholic fatty liver disease and type 2 diabetes: a randomized, double-blind, placebo-controlled clinical trial. Diabetes Ther. 2021;12:843\u201361. https:\/\/doi.org\/10.1007\/s13300-021-01011-3.","journal-title":"Diabetes Ther"},{"key":"4610_CR24","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1007\/s10620-019-5477-1","volume":"65","author":"LL Lai","year":"2020","unstructured":"Lai LL, Vethakkan SR, Nik Mustapha NR, et al. Empagliflozin for the treatment of nonalcoholic steatohepatitis in patients with type 2 diabetes mellitus. Dig Dis Sci. 2020;65:623\u201331. https:\/\/doi.org\/10.1007\/s10620-019-5477-1.","journal-title":"Dig Dis Sci"},{"key":"4610_CR25","doi-asserted-by":"publisher","first-page":"2064","DOI":"10.2337\/dc21-2049","volume":"45","author":"Y Takeshita","year":"2022","unstructured":"Takeshita Y, Honda M, Harada K, et al. Comparison of Tofogliflozin and glimepiride effects on nonalcoholic fatty liver disease in participants with type 2 diabetes: a randomized, 48-week, open-label, active-controlled trial. Diabetes Care. 2022;45:2064\u201375. https:\/\/doi.org\/10.2337\/dc21-2049.","journal-title":"Diabetes Care"},{"key":"4610_CR26","doi-asserted-by":"publisher","first-page":"e001990","DOI":"10.1136\/bmjdrc-2020-001990","volume":"9","author":"M Yoneda","year":"2021","unstructured":"Yoneda M, Honda Y, Ogawa Y, et al. Comparing the effects of Tofogliflozin and Pioglitazone in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus (ToPiND study): a randomized prospective open-label controlled trial. BMJ Open Diab Res Care. 2021;9:e001990. https:\/\/doi.org\/10.1136\/bmjdrc-2020-001990.","journal-title":"BMJ Open Diab Res Care"},{"key":"4610_CR27","doi-asserted-by":"publisher","first-page":"58353","DOI":"10.18632\/oncotarget.16874","volume":"8","author":"K Obara","year":"2017","unstructured":"Obara K, Shirakami Y, Maruta A, et al. Preventive effects of the sodium glucose cotransporter 2 inhibitor Tofogliflozin on diethylnitrosamine-induced liver tumorigenesis in obese and diabetic mice. Oncotarget. 2017;8:58353\u201363. https:\/\/doi.org\/10.18632\/oncotarget.16874.","journal-title":"Oncotarget"},{"key":"4610_CR28","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.3390\/biomedicines10051032","volume":"10","author":"YJ Heo","year":"2022","unstructured":"Heo YJ, Lee N, Choi SE, et al. Empagliflozin reduces the progression of hepatic fibrosis in a mouse model and inhibits the activation of hepatic stellate cells via the Hippo signalling pathway. Biomedicines. 2022;10:1032. https:\/\/doi.org\/10.3390\/biomedicines10051032.","journal-title":"Biomedicines"},{"key":"4610_CR29","doi-asserted-by":"publisher","first-page":"6696","DOI":"10.3390\/ijms23126696","volume":"23","author":"T Puengel","year":"2022","unstructured":"Puengel T, Lefere S, Hundertmark J, et al. Combined therapy with a CCR2\/CCR5 antagonist and FGF21 analogue synergizes in ameliorating steatohepatitis and fibrosis. Int J Mol Sci. 2022;23:6696. https:\/\/doi.org\/10.3390\/ijms23126696.","journal-title":"Int J Mol Sci"},{"key":"4610_CR30","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1111\/iep.12008","volume":"94","author":"M Matsumoto","year":"2013","unstructured":"Matsumoto M, Hada N, Sakamaki Y, et al. An improved mouse model that rapidly develops fibrosis in non-alcoholic steatohepatitis. Int J Exp Pathol. 2013;94:93\u2013103. https:\/\/doi.org\/10.1111\/iep.12008.","journal-title":"Int J Exp Pathol"},{"key":"4610_CR31","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s12944-017-0432-7","volume":"16","author":"J Verbeek","year":"2017","unstructured":"Verbeek J, Spincemaille P, Vanhorebeek I, et al. Dietary intervention, but not losartan, completely reverses non-alcoholic steatohepatitis in obese and insulin resistant mice. Lipids Health Dis. 2017;16:46. https:\/\/doi.org\/10.1186\/s12944-017-0432-7.","journal-title":"Lipids Health Dis"},{"key":"4610_CR32","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1002\/hep.20701","volume":"41","author":"DE Kleiner","year":"2005","unstructured":"Kleiner DE, Brunt EM, Natta MV, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005;41:1313\u201321. https:\/\/doi.org\/10.1002\/hep.20701.","journal-title":"Hepatology"},{"key":"4610_CR33","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1016\/s0002-9440(10)63262-2","volume":"165","author":"CR Engwerda","year":"2004","unstructured":"Engwerda CR, Ato M, St\u00e4ger S, et al. Distinct roles for lymphotoxin-alpha and tumor necrosis factor in the control of leishmania donovani infection. Am J Pathol. 2004;165:2123\u201333. https:\/\/doi.org\/10.1016\/s0002-9440(10)63262-2.","journal-title":"Am J Pathol"},{"key":"4610_CR34","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1007\/s12272-022-01410-5","volume":"45","author":"HH Phung","year":"2022","unstructured":"Phung HH, Lee CH. Mouse models of nonalcoholic steatohepatitis and their application to new drug development. Arch Pharm Res. 2022;45:761\u201394. https:\/\/doi.org\/10.1007\/s12272-022-01410-5.","journal-title":"Arch Pharm Res"},{"key":"4610_CR35","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1111\/j.1440-1746.2006.04758.x","volume":"22","author":"JW Park","year":"2007","unstructured":"Park JW, Jeong G, Kim SJ, et al. Predictors reflecting the pathological severity of non-alcoholic fatty liver disease: comprehensive study of clinical and immunohistochemical findings in younger Asian patients. J Gastroenterol Hepatol. 2007;22:491\u20137. https:\/\/doi.org\/10.1111\/j.1440-1746.2006.04758.x.","journal-title":"J Gastroenterol Hepatol"},{"key":"4610_CR36","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1189\/jlb.6A0114-004RR","volume":"96","author":"M Wang","year":"2014","unstructured":"Wang M, You Q, Lor K, et al. Chronic alcohol ingestion modulates hepatic macrophage populations and functions in mice. J Leukoc Biol. 2014;96:657\u201365. https:\/\/doi.org\/10.1189\/jlb.6A0114-004RR.","journal-title":"J Leukoc Biol"},{"key":"4610_CR37","doi-asserted-by":"publisher","first-page":"3024","DOI":"10.1111\/febs.15877","volume":"289","author":"R Thibaut","year":"2022","unstructured":"Thibaut R, Gage MC, Pineda-Torra I, et al. Liver macrophages and inflammation in physiology and physiopathology of non-alcoholic fatty liver disease. FEBS J. 2022;289:3024\u201357. https:\/\/doi.org\/10.1111\/febs.15877.","journal-title":"FEBS J"},{"key":"4610_CR38","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1038\/nature13989","volume":"518","author":"EG Perdiguero","year":"2015","unstructured":"Perdiguero EG, Klapproth K, Schulz C, et al. Tissue-resident macrophages originate from yolk-sac-derived erythro-myeloid progenitors. Nature. 2015;518:547\u201351. https:\/\/doi.org\/10.1038\/nature13989.","journal-title":"Nature"},{"key":"4610_CR39","doi-asserted-by":"publisher","first-page":"10321","DOI":"10.1038\/ncomms10321","volume":"7","author":"CL Scott","year":"2016","unstructured":"Scott CL, Zheng F, De Baetselier P, et al. Bone marrow-derived monocytes give rise to self-renewing and fully differentiated Kupffer cells. Nat Commun. 2016;7:10321. https:\/\/doi.org\/10.1038\/ncomms10321.","journal-title":"Nat Commun"},{"key":"4610_CR40","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1136\/gutjnl-2011-300304","volume":"61","author":"C Baeck","year":"2012","unstructured":"Baeck C, Wehr A, Karlmark KR, et al. Pharmacological Inhibition of the chemokine CCL2 (MCP-1) diminishes liver macrophage infiltration and steatohepatitis in chronic hepatic injury. Gut. 2012;61:416\u201326. https:\/\/doi.org\/10.1136\/gutjnl-2011-300304.","journal-title":"Gut"},{"key":"4610_CR41","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1002\/hep.29544","volume":"67","author":"O Krenkel","year":"2018","unstructured":"Krenkel O, Puengel T, Govaere O, et al. Therapeutic Inhibition of inflammatory monocyte recruitment reduces steatohepatitis and liver fibrosis. Hepatology. 2018;67:1270\u201383. https:\/\/doi.org\/10.1002\/hep.29544.","journal-title":"Hepatology"},{"key":"4610_CR42","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1002\/hep4.1160","volume":"2","author":"AJ Kruger","year":"2018","unstructured":"Kruger AJ, Fuchs BC, Masia R, et al. Prolonged cenicriviroc therapy reduces hepatic fibrosis despite steatohepatitis in a diet-induced mouse model of nonalcoholic steatohepatitis. Hepatol Commun. 2018;2:529\u201345. https:\/\/doi.org\/10.1002\/hep4.1160.","journal-title":"Hepatol Commun"},{"key":"4610_CR43","doi-asserted-by":"publisher","first-page":"11037","DOI":"10.3390\/ijms222011037","volume":"22","author":"M Yang","year":"2021","unstructured":"Yang M, Kimchi ET, Staveley-O\u2019Carroll KF, et al. Astaxanthin prevents diet-induced NASH progression by shaping intrahepatic immunity. Int J Mol Sci. 2021;22:11037. https:\/\/doi.org\/10.3390\/ijms222011037.","journal-title":"Int J Mol Sci"},{"key":"4610_CR44","doi-asserted-by":"publisher","unstructured":"Alabdulaali B, Al-Rashed F, Al-Onaizi M et al Macrophages and the development and progression of non-alcoholic fatty liver disease. Front Immunol. 2023;14(1195699).https:\/\/doi.org\/10.3389\/fimmu.2023.1195699.","DOI":"10.3389\/fimmu.2023.1195699"},{"key":"4610_CR45","doi-asserted-by":"publisher","first-page":"2579","DOI":"10.1038\/s41401-024-01389-3","volume":"45","author":"XF Lin","year":"2024","unstructured":"Lin XF, Cui XN, Yang J, et al. SGLT2 inhibitors ameliorate NAFLD in mice via downregulating PFKFB3, suppressing Glycolysis and modulating macrophage polarization. Acta Pharmacol Sin. 2024;45:2579\u201397. https:\/\/doi.org\/10.1038\/s41401-024-01389-3.","journal-title":"Acta Pharmacol Sin"},{"key":"4610_CR46","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.ebiom.2017.05.028","volume":"20","author":"L Xu","year":"2017","unstructured":"Xu L, Nagata N, Nagashimada M, et al. SGLT2 Inhibition by empagliflozin promotes fat utilization and Browning and attenuates inflammation and insulin resistance by polarizing M2 macrophages in diet-induced obese mice. EBioMedicine. 2017;20:137\u201349. https:\/\/doi.org\/10.1016\/j.ebiom.2017.05.028","journal-title":"EBioMedicine"},{"key":"4610_CR47","doi-asserted-by":"publisher","first-page":"2212","DOI":"10.1016\/S0140-6736(20)32511-3","volume":"397","author":"EE Powell","year":"2021","unstructured":"Powell EE, Wong VWS, Rinella M. Non-alcoholic fatty liver disease. Lancet. 2021;397:2212\u201324. https:\/\/doi.org\/10.1016\/S0140-6736(20)32511-3.","journal-title":"Lancet"},{"key":"4610_CR48","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1016\/j.metabol.2015.12.012","volume":"65","author":"E Buzzetti","year":"2016","unstructured":"Buzzetti E, Pinzani M, Tsochatzis EA. The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD). Metabolism. 2016;65:1038\u201348. https:\/\/doi.org\/10.1016\/j.metabol.2015.12.012.","journal-title":"Metabolism"},{"key":"4610_CR49","doi-asserted-by":"publisher","first-page":"824","DOI":"10.3390\/biom12060824","volume":"12","author":"F Nassir","year":"2022","unstructured":"Nassir F. NAFLD: Mechanisms, treatments, and biomarkers. Biomolecules. 2022;12:824. https:\/\/doi.org\/10.3390\/biom12060824.","journal-title":"Biomolecules"},{"key":"4610_CR50","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1038\/s41575-018-0009-6","volume":"15","author":"S Schuster","year":"2018","unstructured":"Schuster S, Cabrera D, Arrese M, et al. Triggering and resolution of inflammation in NASH. Nat Rev Gastroenterol Hepatol. 2018;15:349\u201364. https:\/\/doi.org\/10.1038\/s41575-018-0009-6.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"4610_CR51","doi-asserted-by":"publisher","first-page":"5651","DOI":"10.1002\/cncr.24687","volume":"115","author":"AB Siegel","year":"2009","unstructured":"Siegel AB, Zhu AX. Metabolic syndrome and hepatocellular carcinoma: two growing epidemics with a potential link. Cancer. 2009;115:5651\u201361. https:\/\/doi.org\/10.1002\/cncr.24687.","journal-title":"Cancer"},{"key":"4610_CR52","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1002\/hep.20750","volume":"42","author":"EE Powell","year":"2005","unstructured":"Powell EE, Jonsson JR, Clouston AD. Steatosis: co-factor in other liver diseases. Hepatology. 2005;42:5\u201313. https:\/\/doi.org\/10.1002\/hep.20750.","journal-title":"Hepatology"},{"key":"4610_CR53","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1248\/bpb.b17-01007","volume":"41","author":"T Takasu","year":"2018","unstructured":"Takasu T, Takakura S. Protective effect of Ipragliflozin on pancreatic islet cells in obese type 2 diabetic db\/db mice. Biol Pharm Bull. 2018;41:761\u201369. https:\/\/doi.org\/10.1248\/bpb.b17-01007.","journal-title":"Biol Pharm Bull"},{"key":"4610_CR54","doi-asserted-by":"publisher","first-page":"112246","DOI":"10.1016\/j.biopha.2021.112246","volume":"144","author":"S Hojn\u00e1","year":"2021","unstructured":"Hojn\u00e1 S, Rauchov\u00e1 H, Mal\u00ednsk\u00e1 H, et al. Antihypertensive and metabolic effects of empagliflozin in Ren-2 Transgenic rats, an experimental non-diabetic model of hypertension. Biomed Pharmacother. 2021;144:112246. https:\/\/doi.org\/10.1016\/j.biopha.2021.112246.","journal-title":"Biomed Pharmacother"},{"key":"4610_CR55","doi-asserted-by":"publisher","first-page":"155612","DOI":"10.1016\/j.metabol.2023.155612","volume":"145","author":"HJ Chun","year":"2023","unstructured":"Chun HJ, Kim ER, Lee M, et al. Increased expression of sodium-glucose cotransporter 2 and O-GlcNAcylation in hepatocytes drives non-alcoholic steatohepatitis. Metabolism. 2023;145:155612. https:\/\/doi.org\/10.1016\/j.metabol.2023.155612.","journal-title":"Metabolism"},{"key":"4610_CR56","doi-asserted-by":"publisher","first-page":"111738","DOI":"10.1016\/j.biopha.2021.111738","volume":"140","author":"N Yoshioka","year":"2021","unstructured":"Yoshioka N, Tanaka M, Ochi K, et al. The sodium-glucose cotransporter-2 inhibitor Tofogliflozin prevents the progression of nonalcoholic steatohepatitis-associated liver tumors in a novel murine model. Biomed Pharmacother. 2021;140:111738. https:\/\/doi.org\/10.1016\/j.biopha.2021.111738.","journal-title":"Biomed Pharmacother"},{"key":"4610_CR57","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1124\/jpet.120.000046","volume":"375","author":"M Ookawara","year":"2020","unstructured":"Ookawara M, Matsuda K, Watanabe M, et al. The GPR40 full agonist SCO-267 improves liver parameters in a mouse model of nonalcoholic fatty liver disease without affecting glucose or body weight. J Pharmacol Exp Ther. 2020;375:21\u20137. https:\/\/doi.org\/10.1124\/jpet.120.000046.","journal-title":"J Pharmacol Exp Ther"},{"key":"4610_CR58","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1002\/jgh3.12274","volume":"4","author":"T Marjot","year":"2019","unstructured":"Marjot T, Green CJ, Charlton CA, et al. Sodium-glucose cotransporter 2 Inhibition does not reduce hepatic steatosis in overweight, insulin-resistant patients without type 2 diabetes. JGH Open. 2019;4:433\u201340. https:\/\/doi.org\/10.1002\/jgh3.12274.","journal-title":"JGH Open"},{"key":"4610_CR59","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1016\/j.jhep.2023.06.003","volume":"79","author":"ME Rinella","year":"2023","unstructured":"Rinella ME, Lazarus JV, Ratziu V, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. J Hepatol. 2023;79:1542\u201356. https:\/\/doi.org\/10.1016\/j.jhep.2023.06.003.","journal-title":"J Hepatol"},{"key":"4610_CR60","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1002\/path.4829","volume":"241","author":"JKC Lau","year":"2017","unstructured":"Lau JKC, Zhang X, Yu J. Animal models of non-alcoholic fatty liver disease: current perspectives and recent advances. J Pathol. 2017;241:36\u201344. https:\/\/doi.org\/10.1002\/path.4829.","journal-title":"J Pathol"},{"key":"4610_CR61","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1124\/jpet.112.191593","volume":"341","author":"M Suzuki","year":"2012","unstructured":"Suzuki M, Honda K, Fukazawa M, et al. Tofogliflozin, a potent and highly specific sodium\/glucose cotransporter 2 inhibitor, improves glycemic control in diabetic rats and mice. J Pharmacol Exp Ther. 2012;341:692\u2013701. https:\/\/doi.org\/10.1124\/jpet.112.191593.","journal-title":"J Pharmacol Exp Ther"},{"key":"4610_CR62","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","volume":"381","author":"JJV McMurray","year":"2019","unstructured":"McMurray JJV, Solomon SD, Inzucchi SE, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019;381:1995\u20132008. https:\/\/doi.org\/10.1056\/NEJMoa1911303.","journal-title":"N Engl J Med"},{"key":"4610_CR63","doi-asserted-by":"publisher","first-page":"e028739","DOI":"10.1161\/JAHA.122.028739","volume":"12","author":"GM Chertow","year":"2023","unstructured":"Chertow GM, Correa-Rotter R, Vart P, et al. Effects of Dapagliflozin in chronic kidney disease, with and without other cardiovascular medications: DAPA-CKD trial. J Am Heart Assoc. 2023;12:e028739. https:\/\/doi.org\/10.1161\/JAHA.122.028739.","journal-title":"J Am Heart Assoc"},{"key":"4610_CR64","doi-asserted-by":"publisher","first-page":"3107","DOI":"10.3390\/ijms23063107","volume":"23","author":"T Androutsakos","year":"2022","unstructured":"Androutsakos T, Nasiri-Ansari N, Bakasis AD, et al. SGLT-2 inhibitors in NAFLD: expanding their role beyond diabetes and cardioprotection. Int J Mol Sci. 2022;23:3107. https:\/\/doi.org\/10.3390\/ijms23063107.","journal-title":"Int J Mol Sci"}],"container-title":["BMC Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12876-026-04610-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-026-04610-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-026-04610-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T01:04:59Z","timestamp":1770771899000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12876-026-04610-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,15]]},"references-count":64,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4610"],"URL":"https:\/\/doi.org\/10.1186\/s12876-026-04610-1","relation":{},"ISSN":["1471-230X"],"issn-type":[{"value":"1471-230X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,15]]},"assertion":[{"value":"19 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All experiments were approved by the Animal Experiment Committee of the University of Miyazaki (2023\u2009\u2212\u2009507).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"108"}}